Screening Feature Genes of Venous Thromboembolism with DNA Microarray

Chemical Biology & Drug Design
Tao ZhouYanan Guo

Abstract

We aimed to explore the potential genes or pathways related to venous thromboembolism (VTE) and expected our findings could contribute to the development of new target drugs for VTE. The gene expression profile of GSE19151 was downloaded from Gene Expression Omnibus (GEO) database. The bioinformatics methods were applied to screen the feature genes and pathways related with VTE. A total of 115 DEGs were identified, including 25 downregulated genes and 90 upregulated genes. Function enrichment analysis showed that upregulated genes of VTE were mainly enriched in ribosome and translation-related pathways, while downregulated genes were mainly enriched in cytoskeletal protein binding and non-membrane-bounded organelle-related pathways. MCL1, TP53, and RERE were three outstanding genes involved in the interaction network. The most significant pathways enriched by module genes were ribosome and oxidative phosphorylation. Moreover, all the products of the 18 genes enriched in ribosome (hsa03010) were ribosomal proteins. Ribosome, translation, actin binding, and non-membrane-bounded organelle pathways were closely related to the development of VTE. Moreover, MCL1, TP53, and RERE might play key roles in the process of VTE.

References

Jan 1, 1992·Genes, Chromosomes & Cancer·C Caron de Fromentel, T Soussi
Dec 13, 1984·The New England Journal of Medicine·P C Comp, C T Esmon
Dec 2, 1999·Experimental Cell Research·A Dufner, G Thomas
Jun 8, 2001·Bioinformatics·O TroyanskayaR B Altman
Jan 10, 2003·Nucleic Acids Research·Christian von MeringBerend Snel
Feb 26, 2003·The New England Journal of Medicine·Paul M RidkerUNKNOWN PREVENT Investigators
Aug 15, 2003·The New England Journal of Medicine·Clive KearonUNKNOWN Extended Low-Intensity Anticoagulation for Thrombo-Embolism Investigators
Nov 8, 2003·Science·L GiotJ M Rothberg
Nov 25, 2004·Hematology·José A LópezAgnes Y Y Lee
Jan 13, 2005·American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics·Ming T TsuangC C Liew
Sep 1, 2005·Current Opinion in Allergy and Clinical Immunology·Ulrike Raap, Alexander Kapp
Jul 21, 2006·Pathophysiology of Haemostasis and Thrombosis·Frederick R Rickles
Oct 25, 2006·BMC Bioinformatics·André FujitaMari Cleide Sogayar
May 17, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alok A KhoranaMark B Taubman
Oct 17, 2008·Genomic Medicine·Hamza AzizGeoffrey S Ginsburg
Nov 11, 2008·Nucleic Acids Research·Feifei XiaoTongbin Li
Jan 10, 2009·Nature Protocols·Da Wei HuangRichard A Lempicki
Dec 2, 2009·International Journal of Cancer. Journal International Du Cancer·Reetta HolmilaKirsti Husgafvel-Pursiainen
Feb 19, 2010·Thrombosis Research·Svetlana N Tchaikovski, Jan Rosing
Apr 2, 2010·American Journal of Preventive Medicine·Michele G BeckmanThomas L Ortel
Jun 15, 2010·FEBS Letters·Luke W ThomasSteven W Edwards
Nov 11, 2010·Methods in Molecular Biology·Michael KohlBettina Warscheid
Jan 26, 2012·Blood·Zijun Y Xu-MonetteKen H Young
Jul 4, 2012·The Journal of Clinical Investigation·Nigel Mackman
Dec 12, 2012·The New England Journal of Medicine·Giancarlo AgnelliUNKNOWN AMPLIFY-EXT Investigators
Feb 5, 2013·Nature Immunology·Victor PeperzakDavid M Tarlinton
Mar 27, 2013·Phlebology·P PrandoniM Milan
Jun 22, 2013·Genes & Development·Robert L ThomasÅsa B Gustafsson
Jul 25, 2013·Clinical Advances in Hematology & Oncology : H&O·Jeffrey Weitz

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.